IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares gapped up prior to trading on Tuesday . The stock had previously closed at $45.03, but opened at $47.5650. IPSEN shares last traded at $47.5650, with a volume of 142 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Jefferies Financial Group downgraded shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN has a consensus rating of “Hold”.

IPSEN Price Performance

The company has a 50-day moving average price of $45.85 and a two-hundred day moving average price of $46.04.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).